Trial · NCT03350620
Adverse events168
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 168
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nasopharyngitis | Infections and infestations | Stage 1: NVK-002 Concentration 1 | 17 | 164 | |
| other | nasopharyngitis | Infections and infestations | Stage 1: NVK-002 Concentration 2 | 30 | 247 | |
| other | nasopharyngitis | Infections and infestations | Stage 1: Vehicle (Placebo) | 22 | 162 | |
| other | nasopharyngitis | Infections and infestations | Stage 2: NVK-002 Concentration 1 | 14 | 159 | |
| other | nasopharyngitis | Infections and infestations | Stage 2: NVK-002 Concentration 2 | 5 | 162 | |
| other | nasopharyngitis | Infections and infestations | Stage 2: Vehicle (Placebo) | 6 | 99 | |
| other | COVID-19 | Infections and infestations | Stage 1: NVK-002 Concentration 1 | 9 | 164 | |
| other | COVID-19 | Infections and infestations | Stage 1: NVK-002 Concentration 2 | 27 | 247 | |
| other | COVID-19 | Infections and infestations | Stage 1: Vehicle (Placebo) | 18 | 162 | |
| other | COVID-19 | Infections and infestations | Stage 2: NVK-002 Concentration 1 | 14 | 159 | |
| other | COVID-19 | Infections and infestations | Stage 2: NVK-002 Concentration 2 | 13 | 162 | |
| other | COVID-19 | Infections and infestations | Stage 2: Vehicle (Placebo) | 8 | 99 | |
| other | influenza | Infections and infestations | Stage 1: NVK-002 Concentration 1 | 6 | 164 | |
| other | influenza | Infections and infestations | Stage 1: NVK-002 Concentration 2 | 8 | 247 | |
| other | influenza | Infections and infestations | Stage 1: Vehicle (Placebo) | 12 | 162 | |
| other | influenza | Infections and infestations | Stage 2: NVK-002 Concentration 1 | 4 | 159 | |
| other | influenza | Infections and infestations | Stage 2: NVK-002 Concentration 2 | 2 | 162 | |
| other | influenza | Infections and infestations | Stage 2: Vehicle (Placebo) | 2 | 99 | |
| other | hordeolum | Infections and infestations | Stage 1: NVK-002 Concentration 1 | 3 | 164 | |
| other | hordeolum | Infections and infestations | Stage 1: NVK-002 Concentration 2 | 10 | 247 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03350620/events